Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities (2016 - 2025)

Enanta Pharmaceuticals' Total Non-Current Liabilities history spans 14 years, with the latest figure at $202.6 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 14.35% year-over-year to $202.6 million; the TTM value through Dec 2025 reached $202.6 million, down 14.35%, while the annual FY2025 figure was $215.8 million, 12.86% down from the prior year.
  • Total Non-Current Liabilities reached $202.6 million in Q4 2025 per ENTA's latest filing, down from $215.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $256.9 million in Q2 2023 to a low of $30.7 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $149.7 million, with a median of $209.2 million recorded in 2025.
  • Peak YoY movement for Total Non-Current Liabilities: dropped 16.89% in 2022, then surged 448.55% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $55.7 million in 2021, then decreased by 16.89% to $46.3 million in 2022, then soared by 409.83% to $236.0 million in 2023, then grew by 0.26% to $236.6 million in 2024, then dropped by 14.35% to $202.6 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Total Non-Current Liabilities are $202.6 million (Q4 2025), $215.8 million (Q3 2025), and $221.5 million (Q2 2025).